Sinovac Vac also called the Sinovac COPEVAC vaccine, is a protein-based, live-virus vaccine that is produced by the Chinese pharmaceutical company Sinovac Biotech. It was originally intended to be a replacement or a complementary treatment for the existing World Health Organization vaccines like Rotavirus and Pneumococcal vaccine. The main goal of the development of Sinovac was to develop a safe, efficient, and adaptable covid vaccine to replace or augment the currently available vaccines. The main aim was to develop an effective human immunodeficiency virus (HIV) prevention and treatment strategy.
straits times : Currently there are more than 40 countries who are involved in the ratifying process of the CVC vaccination against hepatitis B, Cipro, and Q fever, and several other diseases. One of the major problems that arise during the ratifying process is the absence of regulatory guidelines on the manufacturing of the live-virus vaccines. Some developing countries have made it compulsory for all manufacturing companies to conform to stringent quality control measures. The primary function of the ratifying committee is to ensure the quality of the product.
Sinovac biotech had conducted several research projects aimed at finding better ways of protecting the world's population from the disastrous effects of infectious diseases. The main objective of this pharmaceutical company was to find ways of producing a less toxic vaccine that will prevent the introduction of smallpox, diphtheria, and typhoid into the general population. In addition, this company's aim was also to develop vaccines for various other diseases targeting different forms of bacteria, fungi, and viruses. This company has been successful in completing several vaccine projects and is now offering vaccines for such diseases as Meningitis, Poliomyelitis, Shingles, Mumps, Rubella, and Giardia.
Sinovac Biotech had also received a contract from the Food and Drug Administration (FDA) for the manufacture of influenza.The development of the sinovac vaccine was achieved through a dedicated effort of the Sinovac biotech research department headed by an eminent immunologist, Dr. Richard F. Kishin. It was decided to launch a manufacturing facility in Tokyo, Japan, to manufacture the vaccine by the end of February, twenty-first year of operation. Initially, only the Philippines and Japan were targeted with this project, later it was expanded to include other countries in the region. By the end of February, this pharmaceutical factory had established several hundred pharmacists and technicians and was producing around seventy thousand doses of vaccine each month. At the beginning, the facility was mainly focused on producing standard proteins used for the vaccine production process. However, as the production went on and more batches of vaccine were produced, it was found that this was not sufficient to meet the demand of the market and it had to be diversified into other areas.
In late January or early February, the Sinovac plant received a shipment of Lufenuron tablets from the United States. These tablets contain MPA toxin, one of the most toxic agents available in the market and was previously used in fatal conditions such as a heart attack or cancer. However, there have been no fatalities reported from the use of the Lufenuron tablets and the company is still on trial basis, due to safety trials due to start in November.
Sinovac has yet to finalize the date of the final release of the vaccine.At the time of going to press, the company had released details of the first clinical trial, which is scheduled to start in November in the United States. Two hundred and ninety volunteers are being invited and they will be vaccinated between twenty-four and thirty-one days before the end of April, the remainder of the month for the next quarter.
Sinovac is working on two types of vaccine candidates, both of which will be used to target different forms of HPV, including genital warts, strains associated with genital infections and high-risk women. Sinovac hopes that the vaccine candidates will be ready for the second phase of clinical trials by the end of 2021, once all of the data from the first phase is analyzed and accredited. Sinovac expects the technology to be available for inclusion in clinical trials in Japan, Korea, and China later on.